Clinical Trials Browser

Phase 1/2 × acalabrutinib × 30 days × Clear all

NCT05256641 2026-03-10

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse